Masahiro Takeuchi - Concepedia

Author

Masahiro Takeuchi

Also Known As

H Okuyama, Kazuhiro Yoshida, M Takeuchi, M. Takeuchi, M., Takeuchi, MASAHIRO TAKEUCHI, Manabu Takeuchi, Masahiro TAKEUCHI, Masahiro Takeuchi, Masahiro Takeuchi Madoka Takeuchi

362

Publications

11.6K

Citations

H-Index

233

Concepts

All Affiliations

Kitasato University The University of Tokyo Showa University Fujigaoka Hospital Astellas Pharma (Japan)Nihon University

About

Masahiro Takeuchi is an author at Kitasato University specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	56	7K
2	Engineering	14	17	545
3	Health Sciences	11	13	486
4	Natural Sciences	4	4	170
5	Education	1	1	14

Masahiro Takeuchi

125

Publications

10.8K

Citations

H-Index

Page 1

	Year	Citations
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Wasaburo Koizumi, Hiroyuki Narahara, Takuo Hara, The Lancet Oncology Surgical OncologySpirits TrialGastrointestinal OncologyAdvanced Gastric CancerMedicine	2008	1.9K
TRAF6 is a signal transducer for interleukin-1 Zhaodan Cao, Jessie Xiong, Masahiro Takeuchi, Nature InflammationCytokineSignal TransductionImmunologySignal Transducer	1996	1.3K
Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis Hajime Uno, Brian Claggett, Lü Tian, Journal of Clinical Oncology Retrospective Cohort StudyBetween-group DifferenceCancer EpidemiologyHazard RatioMedicine	2014	721
YM155, a Novel Small-Molecule Survivin Suppressant, Induces Regression of Established Human Hormone-Refractory Prostate Tumor Xenografts Takahito Nakahara, Masahiro Takeuchi, Isao Kinoyama, Cancer Research UrologyInduces RegressionChemoprevention StrategyMedicineHormone-refractory Prostate Cancer	2007	502
The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex Hong-Bing Shu, Masahiro Takeuchi, David V. Goeddel Proceedings of the National Academy of Sciences	1996	420
Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial Kazuhiro Yoshida, Yasuhiro Kodera, Mitsugu Kochi, Journal of Clinical Oncology	2019	381
Anatomy of TRAF2 Masahiro Takeuchi, Mike Rothe, David V. Goeddel Journal of Biological Chemistry	1996	302
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio Kyongsun Pak, Hajime Uno, Dae Hyun Kim, JAMA Oncology	2017	251
The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations Koji Tsuta, Mitsumasa Kawago, Eisuke Inoue, Lung Cancer Disease PrognosisOncogenic AgentMedicineImmunologyGenetic Epidemiology	2013	241
Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes Hirofumi Makino, Masakazu Haneda, Tetsuya Babazono, Diabetes Care Angiotensin Ii BlockerHypertensionRenal PathologyRenal InflammationGlomerulonephritis	2007	226

Page 1